Safety and tolerability of an intratumorally injected DNAzyme, Dz13, in patients with nodular basal-cell carcinoma: a phase 1 first-in-human trial (DISCOVER)

Safety and tolerability of an intratumorally injected DNAzyme, Dz13, in patients with nodular basal-cell carcinoma: a phase 1 first-in-human trial (DISCOVER)

Background The nuclear transcription factor c-Jun is preferentially expressed in basal-cell carcinoma. Dz13 is a deoxyribozyme that targets JUN messenger RNA and has inhibited the growth of a range of tumours in mice. We did a phase 1 study to assess safety and tolerability in human beings. Methods...

Full description

Bibliographic Details
Main Authors: Cho, Eun-Ae (Author), Au-Yeung, Annie (Author), China, Carlos (Author), Yosufi, Benafsha (Author), Arkenau, Hendrik-Tobias (Author), Moloney, Fergal J. (Author), Scolyer, Richard A. (Author), Raftery, Mark J. (Author), Deng, Jason Z. (Contributor), Morton, Stephen Winford (Contributor), Damian, Diona L. (Author), Francis, Douglas J. (Author), Chesterman, Colin N. (Author), Barnetson, Ross St. C. (Author), Halliday, Gary M. (Author), Khachigian, Levon M. (Author), Cai, Hong, Ph. D. Massachusetts Institute of Technology (Author), Hammond, Paula T (Author)
Other Authors: Massachusetts Institute of Technology. Department of Chemical Engineering (Contributor), Koch Institute for Integrative Cancer Research at MIT (Contributor), Hammond, Paula T. (Contributor)
Format: Article
Language:English
Published: Elsevier, 2016-02-12T20:43:26Z.
Subjects:
Article
Online Access:Get fulltext

Internet

Get fulltext

Similar Items